Clinical trial • Phase I • Neurology
Clinical trial in Neuropathic pain
Phase I trial for Neuropathic pain. 18 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Neuropathic pain
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 14-08-2024
- First CTIS Authorization Date
- 29-10-2024
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 18
Eligibility
Recruits 18 Vulnerable population not selected; trial population = Healthy volunteers; no special consent/assent handling described in source.
- Vulnerable Population
- Vulnerable population not selected; trial population = Healthy volunteers; no special consent/assent handling described in source
Recruitment
- Planned Sample Size
- 18
- Recruitment Window Months
- 9
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 18
Germany
- Earliest CTIS Part Ii Submission Date
- 14-10-2024
- Latest Decision Or Authorization Date
- 20-02-2025
- Processing Time Days
- 129
- Number Of Sites
- 1
- Number Of Participants
- 18
Sites
- Site Name
- Medizinische Hochschule Hannover
- Department Name
- Clinic for psychiatry, social psychiatry and psychotherapy Center for Mental Health
- Principal Investigator Name
- Kirsten Müller-Vahl
- Principal Investigator Email
- Mueller-Vahl.Kirsten@mh-hannover.de
- Contact Person Name
- Kirsten Müller-Vahl
- Contact Person Email
- Mueller-Vahl.Kirsten@mh-hannover.de
- Number Of Participants
- 18
Sponsor
Primary sponsor
- Full Name
- Tetra Pharm Technologies ApS
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Related trials
Other published trials that may interest you.
- SZV-1287 for Neuropathic pain
- OCRELIZUMAB for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Secondary progressive multiple sclerosis (active)
- CENOBAMATE for Partial-onset (focal) seizures
- Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
- Clinical trial in Parkinson's disease